Institutional members access full text with Ovid®

Share this article on:

New Drug Treats Metastatic Melanoma

Aschenbrenner, Diane S. MS, RN

AJN The American Journal of Nursing: July 2011 - Volume 111 - Issue 7 - p 25
doi: 10.1097/01.NAJ.0000399309.83160.a5
Drug Watch
  • The newest monoclonal antibody, ipilimumab (Yervoy), is a targeted therapy for late-stage (metastatic) melanoma and is the first drug shown to prolong life in patients with this condition.
  • The drug's most common adverse effects include fatigue, diarrhea, pruritus, rash, and colitis.
  • Ipilimumab can have serious and even life-threatening immune-mediated adverse effects, such as enterocolitis, hepatitis, dermatitis, neuropathy, and endocrinopathy.

Diane S. Aschenbrenner is the course coordinator for undergraduate pharmacology at Johns Hopkins University School of Nursing in Baltimore, MD. She also coordinates Drug Watch:

© 2011 Lippincott Williams & Wilkins, Inc.